- |||||||||| Eucrisa (crisaborole) / Pfizer, Kerydin (tavaborole) / Pfizer
Review, Journal: Boron-Containing heterocycles as promising pharmacological agents. (Pubmed Central) - May 4, 2022
The present perspective is intended to review the pharmacological applications of boron-based heterocycles that have been published. We have classified these compounds into groups exhibiting shared pharmacological activities and discussed their corresponding biological targets focusing mainly on the most potent therapeutic compounds.
- |||||||||| Opzelura (ruxolitinib cream) / Incyte, Maruho
Journal: Evaluating Topical JAK Inhibitors as a Treatment Option for Atopic Dermatitis. (Pubmed Central) - Apr 30, 2022
Topical ruxolitinib is a JAK inhibitor comparable to triamcinolone in efficacy without the adverse effects seen with long-term topical corticosteroid use. Although topical JAK inhibitors have promising efficacy and safety profiles, poor medication adherence common to topical treatments may limit their utility in a clinical setting.
- |||||||||| aspartame/cannabidiol (JW-100) / Jupiter Wellness
Enrollment change, Trial withdrawal, Head-to-Head: Comparison of JW-100 and EUCRISA for the Treatment of Atopic Dermatitis (clinicaltrials.gov) - Mar 4, 2022
P3, N=0, Withdrawn,
These treatment patterns, and the use of dupilumab in particular, after initiating topical therapy may reflect the real-world effectiveness and treatment success of topical regimens during the analysis period. N=184 --> 0 | Not yet recruiting --> Withdrawn
- |||||||||| Eucrisa (crisaborole) / Pfizer
Enrollment closed, Trial primary completion date: Characterizing Skin Microbiome Change in Atopic Dermatitis (clinicaltrials.gov) - Mar 2, 2022
P1, N=20, Active, not recruiting,
N=184 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2021 --> Apr 2022
- |||||||||| Eucrisa (crisaborole) / Pfizer, Xolair (omalizumab) / Roche, Novartis
Journal: An update to the 2013-2014 American Academy of Dermatology (AAD) guidelines for the pharmacological management of atopic dermatitis. (Pubmed Central) - Feb 26, 2022
The AAD guidelines must be updated in the future to include several new treatment modalities that have revolutionized the pharmacologic management of patients with AD, including dupilumab and crisaborole. The future of AD treatment is also extremely bright, as JAK inhibitors and Il-13/31 antibodies have shown convincing results in the improvement of AD patients' lives in various trials and studies that have been examined in this paper.
- |||||||||| Jakafi oral (ruxolitinib) / Novartis, Incyte, Eucrisa (crisaborole) / Pfizer, Opzelura (ruxolitinib cream) / Incyte
Journal: Ruxolitinib (Opzelura) for atopic dermatitis. (Pubmed Central) - Feb 23, 2022
The future of AD treatment is also extremely bright, as JAK inhibitors and Il-13/31 antibodies have shown convincing results in the improvement of AD patients' lives in various trials and studies that have been examined in this paper. No abstract available
- |||||||||| Eucrisa (crisaborole) / Pfizer
Design, synthesis, properties and applications of novel boranol-containing naphthalene analogs (Room 3 (San Diego Convention Center)) - Jan 28, 2022 - Abstract #ACSSp2022ACS_Sp_8720;
To this end, chemoselective transformation of functionalized boron heterocycles has been demonstrated for the synthesis of novel derivatives. The resulting prototypic libraries are tested for antimicrobial, anti-inflammatory, anti-parasitic, and anti-viral activities.
- |||||||||| Eucrisa (crisaborole) / Pfizer
Enrollment change, Trial withdrawal: Topical Crisaborole in Patients With Alopecia Areata (clinicaltrials.gov) - Jan 21, 2022
P2, N=0, Withdrawn,
The resulting prototypic libraries are tested for antimicrobial, anti-inflammatory, anti-parasitic, and anti-viral activities. N=60 --> 0 | Recruiting --> Withdrawn
- |||||||||| Eucrisa (crisaborole) / Pfizer
Clinical, Review, Journal: Advances in the pathophysiology of atopic dermatitis revealed by novel therapeutics and clinical trials. (Pubmed Central) - Jan 12, 2022
The effectiveness of crisaborole reveals that PDE4 contributes to Th2 and Th17/Th22 inflammation and lesional skin barrier dysfunction, while delgocitinib shows that JAK-associated signaling is essential for the inflammatory reaction in AD. This review provides a brief overview of recent research on therapeutic monoclonal antibodies and small biologic molecules for AD and what these treatments reveal about AD pathophysiology.
- |||||||||| Eucrisa (crisaborole) / Pfizer
Trial completion date, Trial primary completion date: Wearable Skin Sensors to Assess Nocturnal Scratch Behavior (clinicaltrials.gov) - Jan 11, 2022
P=N/A, N=15, Recruiting,
This review provides a brief overview of recent research on therapeutic monoclonal antibodies and small biologic molecules for AD and what these treatments reveal about AD pathophysiology. Trial completion date: Nov 2021 --> Apr 2022 | Trial primary completion date: Sep 2021 --> Apr 2022
- |||||||||| Eucrisa (crisaborole) / Pfizer
Trial completion date, Adherence: Eucrisa for Atopic Dermatitis (clinicaltrials.gov) - Dec 17, 2021
P1, N=40, Active, not recruiting,
Trial completion date: Nov 2021 --> Apr 2022 | Trial primary completion date: Sep 2021 --> Apr 2022 Trial completion date: Dec 2021 --> Apr 2022
- |||||||||| Eucrisa (crisaborole) / Pfizer
Preclinical, Journal: Anti-inflammatory effects of a novel phosphodiesterase-4 inhibitor, AA6216, in mouse dermatitis models. (Pubmed Central) - Dec 17, 2021
In a Dermatophagoides farinae-induced dermatitis model, AA6216 significantly reduced the dermatitis score, based on the development of erythema/hemorrhage, scarring/dryness, edema, and excoriation/erosion, compared with a clinically used topical AD drug, tacrolimus. These results suggest the possibility that AA6216 is a novel and effective topical therapeutic agent for the treatment of dermatitis including AD.
- |||||||||| Eucrisa (crisaborole) / Pfizer
Biomarker, Trial completion, Trial completion date, Trial primary completion date: SMART: Skin bioMARkers for Atopic Eczema Therapy Evaluation (clinicaltrials.gov) - Dec 14, 2021
P2, N=37, Completed,
These results suggest the possibility that AA6216 is a novel and effective topical therapeutic agent for the treatment of dermatitis including AD. Recruiting --> Completed | Trial completion date: Apr 2022 --> Sep 2021 | Trial primary completion date: Jan 2022 --> Sep 2021
- |||||||||| Eucrisa (crisaborole) / Pfizer
Trial completion date, Trial primary completion date: Steroid-reducing Effects of Crisaborole (clinicaltrials.gov) - Dec 8, 2021
P4, N=60, Recruiting,
These results are consistent with findings from the previously published network meta-analysis, which used a different methodology for performing indirect treatment comparisons. Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2021 --> Dec 2022
- |||||||||| Eucrisa (crisaborole) / Pfizer
Clinical, P2b data, Journal: A phase 2b, randomized, double-blind, multicenter, vehicle-controlled study to assess the efficacy and safety of two crisaborole regimens in Japanese patients aged 2 years and older with mild-to-moderate atopic dermatitis. (Pubmed Central) - Nov 5, 2021
P2b
Overall, TEAEs were mild; the most frequently reported TEAEs was application site irritation. In summary, both crisaborole regimens, particularly crisaborole BID, demonstrated efficacy and were well tolerated.
- |||||||||| Eucrisa (crisaborole) / Pfizer
Clinical, Clinical guideline, Journal, IO biomarker: Clinical practice guidelines for the diagnosis and management of atopic dermatitis. (Pubmed Central) - Oct 27, 2021
Crisaborole, a new topical phosphodiesterase 4 inhibitor, can be used twice daily in AD patients over three months old. Dupilumab, a biological drug for patients with moderate-to-severe AD, may be considered in patients with no improvement from other systemic treatments.
- |||||||||| aspartame/cannabidiol (JW-100) / Jupiter Wellness
Trial completion date, Trial primary completion date, Head-to-Head: Comparison of JW-100 and EUCRISA for the Treatment of Atopic Dermatitis (clinicaltrials.gov) - Oct 18, 2021
P3, N=184, Not yet recruiting,
This study presents the current state of research on biological drugs in AD. Trial completion date: Jan 2022 --> Apr 2022 | Trial primary completion date: Dec 2021 --> Mar 2022
- |||||||||| Eucrisa (crisaborole) / Pfizer
Trial primary completion date, Adherence: Eucrisa for Atopic Dermatitis (clinicaltrials.gov) - Sep 28, 2021
P1, N=40, Active, not recruiting,
Recruiting --> Completed Trial primary completion date: Sep 2021 --> Dec 2021
- |||||||||| Eucrisa (crisaborole) / Pfizer
Clinical, Journal: Update on pediatric atopic dermatitis. (Pubmed Central) - Sep 22, 2021
Other novel therapies include the topical aryl hydrocarbon receptor agonist tapinarof and oral JAK inhibitors; adolescents are being included in the initial clinical trials for several of these therapies. Dupilumab, the first biologic agent approved for AD, has now been well studied in patients aged 6 years and older, with expanded indication down to 6 years of age.
- |||||||||| Eucrisa (crisaborole) / Pfizer
Journal: Crisaborole 2% Ointment for Mild-to-Moderate Atopic Dermatitis. (Pubmed Central) - Sep 11, 2021
Treatments with tolerable safety profiles such as crisaborole may provide an alternative to patients with TCS phobia. The role of crisaborole in AD therapy may become clearer as multiple phase 4 trials are currently underway and their results are poised to answer more questions, including its safety profile for patients as young as 3 months of age, potential use as a steroid-sparing agent, and direct comparisons to TCS and TCI, which are the current mainstay treatments of mild-to-moderate AD.
- |||||||||| Eucrisa (crisaborole) / Pfizer
Trial completion, Trial completion date, Patient reported outcomes: ASPIRE: PROs & Caregiver Burden in Children With Atopic Dermatitis (clinicaltrials.gov) - Sep 9, 2021
P3, N=92, Completed,
The role of crisaborole in AD therapy may become clearer as multiple phase 4 trials are currently underway and their results are poised to answer more questions, including its safety profile for patients as young as 3 months of age, potential use as a steroid-sparing agent, and direct comparisons to TCS and TCI, which are the current mainstay treatments of mild-to-moderate AD. Recruiting --> Completed | Trial completion date: Oct 2021 --> Aug 2021
- |||||||||| Eucrisa (crisaborole) / Pfizer
Review, Journal: Phosphodiesterase-4 enzyme as a therapeutic target in neurological disorders. (Pubmed Central) - Aug 26, 2021
Subsequently, other PDE4 inhibitors (PDE4Is) like apremilast and crisaborole were approved by the Food and Drug Administration (FDA) for psoriasis, atopic dermatitis etc. Due to the adverse effects like unbearable nausea and vomiting, dose intolerance and diarrhoea, PDE4 inhibitors have very less clinical compliance...This review is an attempt to summarize the data on the effects of PDE4 overexpression in neurological disorders and the use of PDE4Is and newer allosteric modulators as therapeutic options. We have also compiled a list of on-going clinical trials on PDE4 inhibitors in neurological disorders.
- |||||||||| Eucrisa (crisaborole) / Pfizer
Journal: Monovalent antibody-conjugated lipid-polymer nanohybrids for active targeting to desmoglein 3 of keratinocytes to attenuate psoriasiform inflammation. (Pubmed Central) - Aug 18, 2021
To improve the treatment of psoriasiform inflammation, we developed actively targeted nanocarriers loaded with the phosphodiesterase 4 inhibitor AN2728...Intervention with the targeted nanosystem reduced the epidermal thickness of the psoriasiform lesion from 191 to 42 µm, decreased the Psoriasis Area Severity Index by 74%, restored barrier function, and returned chemokine levels to baseline. Our developed nanosystem was safe and demonstrated efficient targeting properties for the treatment of cutaneous inflammation.
- |||||||||| Eucrisa (crisaborole) / Pfizer
Biomarker, Enrollment open, Trial completion date, Trial primary completion date: Response of Children With Atopic Dermatitis (Eczema) to Eucrisa (clinicaltrials.gov) - Aug 2, 2021
P4, N=30, Recruiting,
These results support the efficacious and safe continuous, long-term use of crisaborole for the management of mild-to-moderate AD. Not yet recruiting --> Recruiting | Trial completion date: Jul 2020 --> Jul 2021 | Trial primary completion date: Jul 2020 --> Jul 2021
|
